Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,308,312
  • Shares Outstanding, K 231,144
  • Annual Sales, $ 300 K
  • Annual Income, $ -357,190 K
  • 60-Month Beta 2.90
  • Price/Sales 68,810.40
  • Price/Cash Flow N/A
  • Price/Book 34.29
Trade IMMU with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.73
  • Most Recent Earnings -0.30 on 08/05/20
  • Next Earnings Date 11/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.33
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +48.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.84 +3.56%
on 09/30/20
87.93 -0.08%
on 10/22/20
+2.81 (+3.30%)
since 09/22/20
3-Month
37.85 +132.13%
on 09/04/20
87.93 -0.08%
on 10/22/20
+44.70 (+103.57%)
since 07/22/20
52-Week
8.80 +898.41%
on 04/03/20
87.93 -0.08%
on 10/22/20
+71.77 (+446.05%)
since 10/22/19

Most Recent Stories

More News
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney

BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its...

IMMU : 87.86 (+0.05%)
BYSI : 15.43 (+0.52%)
Adcendo Appoints Michael Pehl as Chief Executive Officer

/PRNewswire/ -- Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of as Chief Executive Officer...

CELGZ : 0.47 (+2.15%)
IMMU : 87.86 (+0.05%)
PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors

PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors

IMMU : 87.86 (+0.05%)
Protara Therapeutics Announces Appointment of Martin Sebastian Olivo, M.D. as Chief Medical Officer

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment...

IMMU : 87.86 (+0.05%)
TARA : 7.24 (-0.96%)
Global Antibody Drug Conjugates Market Size Will Reach USD 4,670 Million By 2026: Facts & Factors

Facts and Factors have published a new research report titled "Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast...

IMGN : 5.90 (-3.28%)
IMMU : 87.86 (+0.05%)
PFE : 43.94 (-0.57%)
PGNX : 4.10 (-9.39%)
SGEN : 161.34 (-2.94%)
Innisfree Advises on More Than $400B Worth of M&A Deals in 2020, Including Successful SPAC Solicitations

Innisfree represented M&A clients in transactions valued at more than $400 billion in 2020, including such high-profile deals as Tiffany's merger with LVMH, Dunkin' Brands acquisition by Inspire Brands,...

IMMU : 87.86 (+0.05%)
MS : 102.91 (-0.62%)
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

GILD : 71.19 (-0.70%)
IMMU : 87.86 (+0.05%)
ICPT : 16.06 (-1.71%)
Conjugated Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

Reportlinker.com announces the release of the report "Conjugated Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05998722/?utm_source=GNW...

DSNKY : 27.8550 (-3.89%)
IMMU : 87.86 (+0.05%)
MRK : 73.61 (+0.77%)
PFE : 43.94 (-0.57%)
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases,...

IMMU : 87.86 (+0.05%)
SCMP : 18.05 (+0.28%)
URGN : 16.95 (-1.11%)
FREQ : 7.52 (+0.13%)
Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in...

TCMD : 44.96 (-1.60%)
PT : 0.9700 (-1.02%)
IMMU : 87.86 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 88.13
1st Resistance Point 88.00
Last Price 87.86
1st Support Level 87.66
2nd Support Level 87.45
3rd Support Level N/A

See More

52-Week High 87.93
Last Price 87.86
Fibonacci 61.8% 57.70
Fibonacci 50% 48.37
Fibonacci 38.2% 39.03
52-Week Low 8.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar